BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
You may also be interested in...
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
BIO President Carl Feldbaum is stepping down after 11 years. His successor will face emerging debate on "generic" biologics and implementation of the Medicare law.
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.